Imeglimin is the first clinical candidate in a new chemical class of oral agents called the glimins by the World Health Organization. Imeglimin acts on the three key organs which play an important role in the current anti-diabetic treatment paradigm: the liver, muscles, and the pancreas.1 In several studies conducted to date, imeglimin has demonstrated potential glucose-lowering effects through increased insulin secretion in response to glucose2, increased insulin sensitivity3, and suppression of gluconeogenesis.4 Imeglimin’s mechanism of action also has the potential to prevent diastolic dysfunction5, 6, 7 and to provide protective effects on beta cell survival and function.8
Over a dozen clinical trials have been conducted studying imeglimin with over 1,200 patients with T2D in the U.S., Europe, and Japan, which have met their primary and secondary endpoints, including a statistically significant decrease of HbA1c and fasting plasma glucose versus placebo with a favorable side effect profile.9 Metavant aims to initiate a Phase 3 program in patients with type 2 diabetes and chronic kidney disease (CKD) stages 3b/4 in the US and Europe.
1 Fouqueray et al., J Diabetes Metab 2011, 2:4.
2 Pacini G et al., Diabetes Obes Metab. 2015;17:541-5.
3 Vial et al., Diabetes, 2015;64:2254-2264.
4 Fouqueray et al., J Diabetes Metab 2011, 2:4.
5 Detaille et al. Cell Death Discovery, 2016; 2,15072.
6 Poster #717, European Association for the Study of Diabetes, 12th–16th September 2016, Munich, Germany.
7 Poster #2054, American Diabetes Association, 9th–13th June 2017, San Diego, USA.
8 Poster #00084 World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, 1st–3rd December 2016, Los Angeles, USA.
9 Fouqueray, P. et al. (2013). 36(3), 565–568.